TL;DR
A cluster randomized trial in 31 pediatric practices found that children in clinics recommending HPV vaccination at ages 9 or 10 were more likely to start and complete the series by age 13 than children in clinics recommending a start at 11 or 12. The findings support considering an earlier recommendation, but current U.S. guidance already allows vaccination to begin at age 9, and the study does not establish a change to national policy.
A cluster randomized trial in 31 U.S. pediatric practices found that children were more likely to start and complete the HPV vaccine series by age 13 when clinics recommended beginning at age 9 or 10, rather than 11 or 12. The results add evidence to discussion of when clinicians should introduce the vaccine, which is used to prevent HPV infections that can lead to several cancers.
The study included 62,271 children and adolescents ages 9 to 13 treated at practices in California and Colorado. Researchers assigned 16 practices to recommend HPV vaccination beginning at ages 9 or 10 and 15 practices to continue recommending a start at ages 11 or 12. By age 13, initiation was recorded for 77.1% of children in the earlier-start group, compared with 67% in the standard-start group. Completion rates were 61.6% and 45.1%, respectively. The study reported adjusted hazard ratios of 2.52 for initiation and 2.85 for completion.
All participating practices received online training on recommending HPV vaccination, annual booster training and practice-level data reviews. The early-start clinics also received guidance on discussing the earlier timing with parents. The research team said the comparison was designed to test the timing of the recommendation, rather than a broad package of different interventions. The median age when children began vaccination was 11.0 years in early-start clinics and 11.8 years in standard-start clinics; median age at completion was 12.2 and 13.3 years, respectively.
The trial did not find differences between the groups in rates of well-child visits at ages 11 or 12, or in meningococcal and Tdap vaccination by age 13. The researchers also reported little difference in parental hesitancy or acceptance. Nearly half of participants were female, and about 22% were covered by Medicaid.
Earlier Recommendations May Improve Completion
The main practical finding is that recommending HPV vaccination earlier was associated with more children completing the series by age 13. That matters because a recommendation given when families are already attending a pediatric visit may make it easier to start the series before other adolescent vaccines and scheduling demands converge. The study also found no reduction in the measured rates of other vaccines or later well-child visits in the early-start practices.
These results do not show that every child will be vaccinated earlier, or that changing the recommendation alone will remove barriers to vaccination. They do offer evidence for clinicians and policymakers weighing whether to move from allowing vaccination at age 9 to more actively recommending it at that age. The study measured vaccination timing and uptake; it did not directly measure changes in HPV infections or cancer outcomes.
As an affiliate, we earn on qualifying purchases.
How U.S. HPV Guidance Sets the Timing
U.S. recommendations already permit a start before age 11. The CDC recommends routine HPV vaccination at ages 11 or 12 and says the series can begin at age 9. The American Academy of Pediatrics recommends starting between ages 9 and 12, at an age the provider considers suitable for acceptance and completion. The trial therefore compared different practice recommendations within the existing age range, rather than testing vaccination outside current guidance.
Sean O’Leary, MD, MPH, of the Children’s Hospital Colorado Anschutz Medical Campus, presented the findings during a press briefing ahead of the IDWeek annual meeting. He said an age-9 visit may be less crowded with vaccines than visits at 11 or 12, when several adolescent vaccines are commonly discussed. He also said an earlier conversation can frame HPV vaccination as cancer prevention. Those are possible explanations offered by the researcher, not outcomes the trial separately tested.
“What our data show is that the age at which families first hear about the HPV vaccine recommendation changes how many children are protected, and how soon.”
— Sean O’Leary, MD, MPH, of the Children’s Hospital Colorado Anschutz Medical Campus
As an affiliate, we earn on qualifying purchases.
What the Trial Does Not Resolve
The findings do not establish whether the same results would occur in pediatric practices outside California and Colorado, or in settings with different patient populations and clinic routines. Although the trial involved many children, the clinics—not individual children—were assigned to the two recommendation approaches. The report describes the study as a cluster randomized trial, but the available material does not provide full details on all possible sources of bias or the durability of the effect beyond age 13.
It is also unclear whether the higher completion rate will translate into different long-term health outcomes. The study focused on vaccine initiation and completion, not subsequent HPV infections or cancers. O’Leary said earlier vaccination does not appear to reduce longer-term protection, but the supplied report does not provide a specific long-term follow-up analysis from this trial. Parents’ concerns also remain relevant: O’Leary said some pushback arose when children expected a well visit without shots.
As an affiliate, we earn on qualifying purchases.
Policy Discussions and Practice Changes
The findings are expected to inform discussions among clinicians and policymakers about whether guidance should more strongly favor starting at age 9 or 10. No change to CDC or American Academy of Pediatrics recommendations is reported in the study material. For now, those guidelines continue to provide the existing age ranges, with the CDC naming 11 or 12 as routine timing while allowing a start at 9.
Further research and policy review will help clarify whether the uptake difference holds across more locations and over longer periods. In the meantime, pediatric practices may weigh how to introduce the vaccine earlier while preparing families for the possibility of vaccination at a well-child visit. The trial’s next significance will depend on whether its results influence formal guidance and whether other studies find similar effects.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the trial find about starting HPV vaccination earlier?
By age 13, initiation was 77.1% in clinics recommending a start at age 9 or 10, compared with 67% in clinics recommending a start at 11 or 12. Completion was 61.6% versus 45.1%.
What age does the CDC recommend for HPV vaccination?
The CDC recommends routine HPV vaccination at ages 11 or 12, while noting that vaccination can begin at age 9.
Did earlier recommendations affect other vaccines or well-child visits?
The study reported no difference between the groups in well-child visit rates at ages 11 or 12, or in meningococcal and Tdap vaccination rates by age 13.
Does the study show that earlier vaccination prevents more cancers?
No. The trial measured vaccine initiation and completion, not HPV infections or cancer outcomes. It found higher uptake with earlier recommendations but did not directly measure resulting changes in disease.
Have national vaccination guidelines changed because of the study?
No guideline change is reported. The study’s lead researcher said policymakers should consider a stronger preference for starting at ages 9 or 10, but current CDC and American Academy of Pediatrics guidance remains as described in the report.
Source: rss
